Introduction
============

Endoscopic retrograde cholangiopancreatography (ERCP) is a widely performed diagnostic and therapeutic procedure for a variety of pancreatobiliary diseases. However, ERCP for patients with surgically altered anatomy is challenging because intubation of a side-viewing duodenoscope is technically difficult and sometimes risky, especially in cases with Roux-en-Y reconstruction [@JR1857-1] . Recently, a balloon endoscope is an emergent treatment modality that has dramatically increased the technical success rate of ERCP for that population [@JR1857-2] [@JR1857-3] [@JR1857-4] [@JR1857-5] [@JR1857-6] [@JR1857-7] [@JR1857-8] . Studies suggest the safety of balloon endoscope-assisted ERCP (BE-ERCP) [@JR1857-9] [@JR1857-10] [@JR1857-11] [@JR1857-12] . but attention should be paid to potential procedure-related adverse events (AEs) including gastrointestinal perforation, aspiration pneumonia, and pancreatitis [@JR1857-13] .

With the aging population, there is an increasing opportunity to perform ERCP for elderly patients. Due to serious comorbidities such as cardiovascular or cerebrovascular diseases, elderly patients receiving therapeutic ERCP may be associated with higher morbidity and mortality compared to non-elderly patients [@JR1857-14] [@JR1857-15] . Elderly people may be predisposed to risk of aspiration pneumonia based on impaired pharyngoglottal reflex and reflexive pharyngeal swallow [@JR1857-16] [@JR1857-17] . Furthermore, clinical evidence suggests an increased risk of gastrointestinal perforation in colonoscopy in the elderly [@JR1857-18] [@JR1857-19] . Although previous retrospective studies showed the safety of standard ERCP or enteroscopy for elderly patients [@JR1857-20] [@JR1857-21] , the safely and feasibility of BE-ERCP have not been fully investigated.

To examine the feasibility of BE-ERCP for the elderly (≥ 75 years), we conducted a large observational study at a single referral center in Japan.

Patients and methods
====================

Study design and population
---------------------------

The current study was a single-center retrospective cohort study to evaluate the safety of BE-ERCP for the elderly. We identified consecutive patients with surgically altered anatomy who underwent BE-ERCP through our prospectively-maintained ERCP database. For patients who underwent multiple BE-ERCP sessions during the study period, we analyzed the first session for each patient. We excluded patients with Billroth-I reconstruction. Clinical outcomes were compared between the elderly (≥ 75 years old) and non-elderly patients (\< 75 years old). The primary outcome was incidence of early AEs associated with BE-ERCP. The secondary outcomes included the technical success rate of BE-ERCP and specific AEs (e. g., aspiration pneumonia, gastrointestinal perforation, and pancreatitis).

This study was conducted according to the guidelines in the Helsinki Declaration and was approved by the ethics committee of the University of Tokyo (Tokyo, Japan). Written informed consent for the procedure was obtained from each patient before the procedure. Consent for the use of data was obtained on the opt-out basis.

Endoscopic procedures
---------------------

Prior to the procedure, we assessed physical status of patients. BE-ERCP was considered as contraindicated when patients were highly disabled (with Eastern Cooperative Oncology Group Performance Status \[PS\] \> 3 or American Society of Anesthesiologists Physical Status Classification score \[ASA-PS\] \> 4), had unstable vital signs (e. g., septic shock, or hypoxia requiring high-volume oxygen), or with dysphagia. For patients who were likely to have dysphagia, otolaryngologists evaluated swallowing function before the procedure. Percutaneous transhepatic biliary drainage (PTBD) was performed for patients who could not undergo BE-ERCP.

ERCP was performed using a short-type double-balloon endoscope (EC-450BI5/EI-530B with a 2.8-mm-wide working channel or EI-580BT with a 3.2-mm-wide working channel; Fujifilm, Tokyo, Japan) with CO ~2~ insufflation. During the study period, EC-450BI5 or EI-530B was initially used and EI-580BT was used since July 2015 [@JR1857-22] . BE-ERCP was performed under moderate sedation with intravenous injection of diazepam or midazolam and pethidine hydrochloride during the procedure, and continuous intravenous administration of dexmedetomidine hydrochloride. The details of BE-ERCP procedures in our institution were reported previously [@JR1857-23] [@JR1857-24] .

Biliary or pancreatic cannulation was attempted via wire-guided or contrast-assisted method using a cannula (MTW Endoskopie, Wesel, Germany) or sphincterotome (Truetome, Boston Scientific Japan, Tokyo, Japan) and a 0.025-inch guidewire (VisiGlide2, Olympus, Tokyo, Japan; Endoselector, Boston Scientific Japan). Sphincteroplasty (endoscopic papillary balloon dilation \[EPBD\] or endoscopic papillary large balloon dilation \[EPLBD\] without sphincterotomy) using a balloon catheter (Hurricane RX or CRE wire-guided balloon dilator, Boston Scientific Japan; ZARA or GIGA2, Century Medical, Tokyo, Japan) was performed before stone extraction for patients with intact papilla, as previously reported [@JR1857-25] [@JR1857-26] [@JR1857-27] . Basket (TetraCatch V and FlowerBasket V, Olympus) and/or balloon catheters (Multi-3V Extraction Balloon, Olympus) were used for the removal of bile duct stones [@JR1857-28] . Endoscopic mechanical lithotripsy (LithoCrushV, Olympus) was performed if needed. Balloon dilation (Hurricane RX, Boston Scientific Japan; REN, Kaneka Medix Corp., Osaka, Japan) was performed for benign strictures of the bile duct, pancreatic duct, and anastomotic strictures. A plastic stent or a metal stent was placed for cases of benign stricture or malignant biliary obstruction [@JR1857-29] .

All patients were admitted to our hospital the day before BE-ERCP, and were discharged in 2 days after the procedure unless they developed AEs.

Definitions of outcome variables
--------------------------------

AEs and their severities were defined according to the lexicon guidelines proposed by American Society of Gastrointestinal Endoscopy [@JR1857-30] . AEs were defined as early when they developed within 14 days of the index ERCP. Severity of early AEs was graded as follows: mild, requiring an unplanned prolongation of hospital stay ≤ 3 days; moderate, requiring an unplanned prolongation of hospital stay for 4 to 10 days, endoscopy, interventional radiology, or admission to the intensive care unit for one night; and severe, requiring an unplanned prolongation of hospital stay for \> 10 days, admission to the intensive care unit for \> 1 night, or surgical intervention. Technical success was defined as successful biliary or pancreatic cannulation, and subsequent stone removal, balloon dilation, or stent placement, if needed [@JR1857-9] .

Statistical analysis
--------------------

Categorical variables were compared using the chi-square test or Fisher's exact test, as appropriate. Continuous variables were compared using the Wilcoxon rank-sum test.

Univariable and multi-variable logistic regression models were used to estimate odds ratios (OR) and corresponding 95 % confidence interval (CI) of early adverse events. The multivariable model included variables with *P*  \< 0.10 in a univariable model in addition to age (≥ 75 vs. \< 75 years old).

For all analyses, a two-sided *P*  \< 0.05 was used to denote statistical significance. All statistical analyses were performed using the EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [@JR1857-31] , which is a graphical user interface for the R software (The R Foundation for Statistical Computing, Vienna, Austria, version 3.4.1).

Results
=======

A total of 1,363 BE-ERCP procedures were performed for 568 patients between January 2010 and September 2019. After excluding repeated BE-ERCP sessions, 211 elderly and 357 non-elderly patients were included for the analyses ( [Fig. 1](#FI1857-1){ref-type="fig"} ).

![Selection of elderly (aged ≥ 75 years old) and non-elderly patients (aged \< 75 years old) who underwent balloon endoscope-assisted endoscopic retrograde cholangiopancreatography. BE-ERCP, balloon endoscope-assisted endoscopic retrograde cholangiopancreatography.](10-1055-a-1216-1363-i1857ei1){#FI1857-1}

[Table 1](#TB1857-1){ref-type="table"} shows baseline characteristics of the study population. As expected, elderly patients were more likely to have higher scores of PS and ASA-PS and take antithrombotic agents regularly as compared with non-elderly patients. BE-ERCP was more likely indicated for bile duct stones in elderly patients than in non-elderly patients. The rates of other indications were comparable between the groups. Overall, the major type of surgery and gastrointestinal reconstruction was gastrectomy with Roux-en-Y reconstruction.

###### Baseline characteristics of elderly and non-elderly patients who underwent balloon endoscope-assisted endoscopic retrograde cholangiopancreatography.

  Characteristic [1](#FN1857-2){ref-type="table-fn"}                    Elderly (n = 211)                     Non-elderly (n = 357)                  *P* value
  --------------------------------------------------------------------- ------------------------------------- -------------------------------------- -----------
  Gender                                                                                                                                             0.007
  Male                                                                  149 (71 %)                            211 (59 %)                             
  Female                                                                 62 (29 %)                            146 (41 %)                             
  Performance status [2](#FN1857-3){ref-type="table-fn"} , 0/1/2/ ≥ 3    72/97/26/16 (34 %/46 %/12 %/7.6 %)   177/151/25/4 (50 %/42 %/7.0 %/1.1 %)    \< 0.001
  ASA-PS score [3](#FN1857-4){ref-type="table-fn"} , 1/2/3/4             35/123/49/4 (17 %/58 %/23 %/1.9 %)   124/151/77/5 (35 %/42 %/22 %/1.4 %)     \< 0.001
  Indication for ERCP                                                                                                                                
  Bile duct stone                                                       112 (53 %)                            124 (35 %)                              \< 0.001
  Benign biliary stricture                                               50 (24 %)                            109 (31 %)                             0.08
  Malignant biliary obstruction                                          30 (14 %)                             59 (17 %)                             0.55
  Cholangitis                                                            15 (7.1 %)                            29 (8.1 %)                            0.75
  Pancreatic intervention                                                 4 (1.9 %)                            36 (10 %)                              \< 0.001
  Type of surgery/GI reconstruction                                                                                                                  
  Gastrectomy/Roux-en-Y                                                  95 (45 %)                             83 (23 %)                              \< 0.001
  Gastrectomy/Billroth-II                                                18 (8.5 %)                            17 (4.8 %)                            0.10
  Pancreaticoduodenectomy/Roux-en-Y                                      25 (12 %)                             54 (15 %)                             0.32
  Pancreaticoduodenectomy/Billroth-II                                    32 (15 %)                             65 (18 %)                             0.42
  Extrahepatic bile duct resection/Roux-en-Y                             20 (9.5 %)                            84 (24 %)                              \< 0.001
  Others                                                                 21 (10 %)                             54 (15 %)                             0.10
  Antithrombotic agents                                                  31 (15 %)                             23 (6.4 %)                            0.002
  Antiplatelet                                                           25 (12 %)                             16 (4.5 %)                            0.002
  Anticoagulant                                                           6 (2.8 %)                             7 (2.0 %)                            0.57
  Type of scope                                                                                                                                      0.34
  EC-450BI5 or EI-530B (2010--2015)                                      88 (42 %)                            164 (46 %)                             
  EI-580BT (2015--2019)                                                 123 (58 %)                            193 (54 %)                             

ASA-PS, American Society of Anesthesiologists Physical Status Classification; ERCP, endoscopic retrograde cholangiopancreatography; GI, gastrointestinal.

Data are expressed as number (percentage) of patients within a given group.

Performance status is defined as follows: 0, fully active, able to carry on all pre-disease performance without restriction; 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2, ambulatory and capable of all self-care but unable to carry out any work activities; 3, capable of only limited self-care; 4, completely disabled; 5, dead.

ASA-PS score is defined as follows: 1, a normal healthy patient; 2, a patient with a mild systemic disease; 3, a patient with a severe systemic disease; 4, a patient with a life-threatening systemic disease; 5, a moribund patient who is not expected to survive without the operation; and 6, a declared brain-dead patient whose organs are removed for donor purposes.

[Table 2](#TB1857-2){ref-type="table"} shows the details of BE-ERCP procedures ( [Fig. 2](#FI1857-2){ref-type="fig"} ). The technical success rates were both 80 % in the elderly and non-elderly groups ( *P*  = 0.91). Median procedure time of BE-ERCP was 69 minutes in the elderly group and 65 minutes in the non-elderly group ( *P*  = 0.49). Reasons for 114 technical failures were failed scope insertion in 53 and failed biliary or pancreatic duct cannulation in 61 (39 with intact papilla, and 22 with pancreatico- or hepatico-jejunostomy). Those patients were successfully managed by PTBD (n = 52), interventional endoscopic ultrasonography (n = 34), repeated BE-ERCP (n = 1), conservative treatment (n = 23), or surgery (n = 4). Compared with non-elderly patients, elderly patients were more likely to undergo EPBD and bile duct stone removal during BE-ERCP. The median number of BE-ERCP sessions during the study period was two in the elderly group and one in the non-elderly group ( *P*  = 0.76).

###### Endoscopic procedures for elderly and non-elderly patients.

  Procedure [1](#FN1857-5){ref-type="table-fn"}          Elderly (n = 211)   Non-elderly (n = 357)   *P* value
  ------------------------------------------------------ ------------------- ----------------------- -----------
  Technical success                                      168 (80 %)          286 (80 %)              0.91
  Total procedure time, minutes                           69 (46--95)         65 (42--95)            0.49
  Successful scope insertion                             196 (93 %)          319 (89 %)              0.18
  Total number of ERCP session during the study period     2 (1--3)            1(1--3)               0.76
  Sphincteroplasty                                                                                   
  EPBD                                                    44 (21 %)           35 (9.8 %)              \< 0.001
  EPLBD                                                   24 (11 %)           23 (6.4 %)             0.06
  Bile duct stone removal                                106 (50 %)          147 (41 %)              0.04
  Lithotripsy                                             19 (9.0 %)          46 (13 %)              0.17
  Balloon dilation                                                                                   
  Biliary stricture                                       38 (18 %)           89 (25 %)              0.06
  Pancreatic stricture                                     1 (0.5 %)          17 (4.8 %)             0.005
  Stent placement                                                                                    
  Biliary                                                 82 (39 %)          113 (32 %)              0.08
  Pancreatic                                               0                   8 (2.2 %)             0.03

EPBD, endoscopic papillary balloon dilation; EPLBD, endoscopic papillary large balloon dilation.

Data are expressed as number (percentage) of patients within a given group or as median (interquartile range).

![Endoscopic and fluoroscopic images of balloon endoscope-assisted endoscopic retrograde cholangiopancreatography. **a** Endoscopic image of bile duct stone removal using a basket catheter. **b** Balloon dilation for benign biliary stricture at the anastomosis of hepaticojejunostomy. **c** Fluoroscopic image of bile duct stone removal using endoscopic mechanical lithotripsy. **d** Biliary stent placement for hepaticojejunostomy anastomotic stricture.](10-1055-a-1216-1363-i1857ei2){#FI1857-2}

Incidences of early AEs were similar between the elderly and non-elderly groups (12 % vs. 9.0 %, *P*  = 0.31; [Table 3](#TB1857-3){ref-type="table"} ). The multivariable-adjusted OR for early AEs comparing elderly to non-elderly patients was 1.36 (95 % CI 0.74--2.51, *P*  = 0.32; [Table 4](#TB1857-4){ref-type="table"} and [Supplementary Table 1](#TB1857-5){ref-type="table"} ). Sensitivity analysis excluding patients with failed scope insertion did not alter our findings (multivariable-adjusted OR 1.25, 95 % CI 0.67--2.32, *P*  = 0.49). Furthermore, analyses including total BE-ERCP sessions also showed similar incidences of early adverse events between the groups (9.5 % vs. 7.2 % in the elderly and non-elderly group, respectively; *P*  = 0.17; [Supplementary Table 2](#TB1857-6){ref-type="table"} ). Gastrointestinal perforation was observed in 2.4 % of the elderly patients and 2.8 % of the non-elderly patients ( *P*  = 0.99). Among the three who developed severe perforation, one elderly patient with Billroth-II reconstruction underwent emergent surgery and the other two (one elderly and one non-elderly patient) were hospitalized for \> 10 days but were managed conservatively without interventions. Furthermore, the rates of gastrointestinal perforation were not different by the type of gastrointestinal reconstruction (2.9 % vs. 2.1 % in patients with Roux-en-Y reconstruction or Billroth-II, respectively; *P*  = 0.86). Aspiration pneumonia was observed in four (1.9 %) elderly patients and two (0.6 %) non-elderly patients ( *P*  = 0.20). median procedure time of these six patients was 119 minutes. The multivariable logistic regression model suggested lengthy procedure (\> 90 minutes) as a risk factor of early AEs (multivariable-adjusted OR 1.98, 95 % CI 1.08--3.60; *P*  = 0.03). Rates of other early AEs including post-ERCP pancreatitis and bleeding were similar between the groups. Any fatal AE was not observed in our study cohort.

###### Incidences and severities of early adverse events associated with balloon endoscope-assisted endoscopic retrograde cholangiopancreatography in elderly and non-elderly patients.

  Early adverse events [1](#FN1857-6){ref-type="table-fn"}                               Elderly (n = 211)   Non-elderly (n = 357)   *P* value
  -------------------------------------------------------------------------------------- ------------------- ----------------------- -----------
  Total                                                                                  25 (12 %)           32 (9.0 %)              0.31
  GI perforation [2](#FN1857-7){ref-type="table-fn"}                                      5 (2.4 %)          10 (2.8 %)              0.99
  Severe                                                                                  2 (0.9 %)           1 (0.3 %)              0.56
  Aspiration pneumonia                                                                    4 (1.9 %)           2 (0.6 %)              0.20
  Severe                                                                                  0                   0                      NA
  Pancreatitis [2](#FN1857-7){ref-type="table-fn"} [3](#FN1857-8){ref-type="table-fn"}    7 (3.3 %)           9 (2.5 %)              0.61
  Severe                                                                                  2 (0.9 %)           0                      0.14
  Bleeding                                                                                1 (0.5 %)           0                      0.37
  Severe                                                                                  0                   0                      NA
  Cholangitis                                                                             7 (3.3 %)          11 (3.1 %)              0.99
  Cholecystitis                                                                           2 (0.9 %)           0                      0.14
  Bile duct injury                                                                        1 (0.5 %)           0                      0.37
  Hoarseness                                                                              1 (0.5 %)           0                      0.37

GI, gastrointestinal; NA, not available.

Data are expressed as number (percentage) of patients within a given group.

One elderly patient developed severe GI perforation and pancreatitis.

Among 16 patients who developed pancreatitis, 11 were with intact papilla, three were with pancreaticojejunostomy, and two were with hepaticojejunostomy.

###### Logistic regression analyses to assess the association of age with incidence of early adverse events associated with balloon endoscope-assisted endoscopic retrograde cholangiopancreatography.

                                    OR (95 % CI)                                   
  -------------- ----- ------------ ------------------- ------ ------------------- ------
  Age                                                                              
   \< 75 years   357   32 (9.0 %)   1 (referent)               1 (referent)        
   ≥ 75 years    211   25 (12 %)    1.37 (0.79--2.37)   0.27   1.36 (0.74--2.51)   0.32

CI, confidence interval; eAE, early adverse event; OR, odds ratio.

To select variables for the final multivariable model, a univariable logistic regression model was examined for each of the following variables: gender (female or male), Performance Status (\< 2 or ≥ 2), American Society of Anesthesiologists Physical Status Classification (≤ 2 or \> 2), indication for endoscopic retrograde cholangiopancreatography (bile duct stone, benign biliary stricture, malignant biliary obstruction, cholangitis, or pancreatic intervention), type of surgery (choledochojejunostomy, gastrectomy, pancreaticoduodenectomy, or other), gastrointestinal reconstruction (Billroth-II, or Roux-en-Y, or other), use of antithrombotic agents (yes or no), type of scope (EC-450BI5/EI-530B or EI-580BT), successful scope insertion (yes or no), bile duct stone removal (yes or no), sphincteroplasty (no, endoscopic papillary balloon dilation, or endoscopic papillary large balloon dilation), balloon dilation for biliary or pancreatic stricture (yes or no), biliary stent placement (yes or no), and procedure time (≤ 90 minutes or \> 90 minutes). In addition to age (≥ 75 years vs. \< 75 years), variables with *P*  \< 0.10 in univariable analyses were entered into the multivariable model. The final model was described in **Supplementary Table 1** .

###### Univariable and multi-variable logistic regression analyses to assess the association of age with incidence of early adverse events associated with balloon endoscope-assisted endoscopic retrograde cholangiopancreatography.

                                                                             OR (95 % CI)                                        
  ------------------------------------------------------ ------ ------------ ------------------- ----------- ------------------- -----------
  Age                                                                                                                            
   \< 75 years                                            357   32 (9.0 %)   1 (referent)                    1 (referent)        
   ≥ 75 years                                             211   25 (12 %)    1.37 (0.79--2.37)   0.27        1.36 (0.74--2.51)   0.32
  Gender                                                                                                                         
  Female                                                  208   20 (9.6 %)   1 (referent)                                        
  Male                                                    360   37 (10 %)    1.08 (0.61--1.91)   0.80                            
  Performance Status                                                                                                             
   \< 2                                                   497   50 (10 %)    1 (referent)                                        
   ≥ 2                                                     71    7 (9.9 %)   0.98 (0.43--2.25)   0.96                            
  ASA-PS                                                                                                                         
   ≤ 2                                                    433   48 (11 %)    1 (referent)                                        
  2                                                       135    9 (6.7 %)   0.57 (0.27--1.20)   0.14                            
  Indication for ERCP                                                                                                            
  BBS                                                     158   17 (11 %)    1 (referent)                    1 (referent)        
  Bile duct stone                                         236   29 (12 %)    1.16 (0.62--2.19)   0.73        0.97 (0.40--2.36)   0.94
  MBO                                                      89    4 (4.5 %)   0.39 (0.13--1.20)   0.10        0.70 (0.20--2.49)   0.58
  Cholangitis                                              45    2 (4.4 %)   0.39 (0.09--1.74)   0.22        1.56 (0.30--8.15)   0.60
  Pancreatic intervention                                  40    5 (13 %)    1.18 (0.41--3.43)   0.76        6.47 (1.67--25.2)   0.007
  Type of surgery                                                                                                                
  Extrahepatic bile duct resection                        110   10 (9.1 %)   1 (referent)                                        
  Gastrectomy                                             217   26 (12 %)    1.36 (0.63--2.94)   0.43                            
  PD                                                      183   16 (8.7 %)   0.96 (0.42--2.19)   0.92                            
  Other                                                    58    5 (8.6 %)   0.94 (0.31--2.90)   0.92                            
  Gastrointestinal reconstruction                                                                                                
  Billroth-II                                             141   13 (9.2 %)   1 (referent)                                        
  Roux-en-Y                                               409   42 (10 %)    1.13 (0.59--2.17)   0.72                            
  Other                                                    18    2 (11 %)    1.23 (0.25--5.96)   0.80                            
  Antithrombotic agents                                                                                                          
  No                                                     4514   53 (10 %)    1 (referent)                                        
  Yes                                                      54    4 (7.4 %)   0.70 (0.24--2.00)   0.50                            
  Type of scope                                                                                                                  
  EI-580BT                                                316   30 (9.5 %)   1 (referent)                                        
  EC-450BI5 or EI-530B                                    252   27 (11 %)    1.14 (0.66--1.98)   0.63                            
  Successful scope insertion                                                                                                     
  No                                                       53    1 (1.9 %)   1 (referent)                    1 (referent)        
  Yes                                                     515   56 (11 %)    6.34 (0.86--46.8)   0.07        1.41 (0.17--11.5)   0.76
  Bile duct stone removal                                                                                                        
  No                                                      315   17 (5.4 %)   1 (referent)                    1 (referent)        
  Yes                                                     253   40 (16 %)    3.29 (1.82--5.96)    \< 0.001   4.37 (1.74--11.0)   0.002
  Sphincteroplasty                                                                                                               
  No                                                      442   38 (8.6 %)   1 (referent)                    1 (referent)        
  EPBD                                                     79    8 (10 %)    1.20 (0.54--2.67)   0.66        0.59 (0.21--1.61)   0.30
  EPLBD                                                    47   11 (23 %)    3.25 (1.53--6.90)   0.002       1.47 (0.55--3.91)   0.45
  Balloon dilation for biliary or pancreatic stricture                                                                           
  No                                                        3   38 (11 %)    1 (referent)                                        
  Yes                                                     139   18 (13 %)    1.26 (0.70--2.30)   0.44                            
  Biliary stent placement                                                                                                        
  No                                                      373   27 (7.2 %)   1 (referent)                    1 (referent)        
  Yes                                                     195   30 (15 %)    2.33 (1.34--4.05)   0.003       3.22 (1.65--6.26)    \< 0.001
  Procedure time                                                                                                                 
   ≤ 90 minutes                                           411   31 (7.5 %)   (referent)                      (referent)          
   \> 90 minutes                                          157   26 (17 %)    2.43 (1.39--4.25)   0.002       1.98 (1.08--3.60)   0.03

ASA-PS, American Society of Anesthesiologists Physical Status Classification; BBS, benign biliary stricture; CI, confidence interval; eAE, early adverse event; EPBD, endoscopic papillary balloon dilation; EPLBD, endoscopic papillary large balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; GI, gastrointestinal; MBO, malignant biliary obstruction; OR, odds ratio; PD pancreaticoduodenectomy.

In addition to age, variables with P \< 0.10 in univariable analyses were entered into the multivariable model.

###### Incidences and severities of early adverse events associated with balloon endoscope-assisted endoscopic retrograde cholangiopancreatography in all procedure sessions during the study period.

  Early adverse events [1](#FN1857-11){ref-type="table-fn"}   Elderly (n = 465)   Non-elderly (n = 898)   *P* value
  ----------------------------------------------------------- ------------------- ----------------------- -----------
  Total                                                       44 (9.5 %)          65 (7.2 %)              0.17
  GI perforation†                                             11 (2.4 %)          14 (1.6 %)              0.29
  Severe                                                       5 (1.1 %)           1 (0.1 %)              0.02
  Aspiration pneumonia                                        10 (2.2 %)           2 (0.2 %)               \< 0.001
  Severe                                                       0                   0                      NA
  Pancreatitis                                                 7 (1.5 %)          19 (2.1 %)              0.53
  Severe                                                       2 (0.4 %)           0                      0.12
  Bleeding                                                     2 (0.4 %)           4 (0.4 %)              0.99
  Severe                                                       0                   1 (0.1 %)              0.99
  Cholangitis                                                 11 (2.4 %)          25 (2.8 %)              0.72
  Cholecystitis                                                3 (0.6 %)           0                      0.04
  Other                                                        4 (0.9 %)          2 (0.2 %)               0.19

GI, gastrointestinal; NA, not available.

Data are expressed as number (percentage) of patients within a given group.

Discussion
==========

The current study was a large-scale retrospective study including 568 patients to evaluate the feasibility of BE-ERCP for the elderly. The early AEs associated with BE-ERCP were observed in 12 % of elderly patients compared with 9.0 % of non-elderly patients. Furthermore, incidences of gastrointestinal perforation and aspiration pneumonia were similar between the elderly and non-elderly groups, and the high technical success rate (80 %) was achieved in both groups.

Despite higher likelihood of regular use of antithrombotic agents and impaired physical activity in elderly patients, our study suggested the feasibility of BE-ERCP for this patient population. Incidence of early AEs related to BE-ERCP was reported to be 1.6 % to 12.5 % [@JR1857-6] [@JR1857-9] [@JR1857-13] [@JR1857-23] [@JR1857-32] [@JR1857-33] . In a recent large-scale, multicenter prospective, study including 311 patients receiving BE-ERCP, the rate of early AEs was 10.6 % [@JR1857-9] . Of note, the current study showed comparable incidences of early AEs to those reported in the previous studies. Furthermore, no fatal AE was observed in the elderly group in our study cohort. In addition, intended procedures were successfully performed for the majority of our elderly patients. Taken together, BE-ERCP may become a first-line non-surgical treatment strategy for elderly patients with surgically altered anatomy.

Aspiration pneumonia is a commonly encountered disease among geriatric patients with dysphagia [@JR1857-34] . Prevalence of oropharyngeal dysphagia was reported to be 13 % of individuals aged over 65 years, and the risk can be further enhanced if they concomitantly have neurological comorbidity, frailty, or advanced age [@JR1857-35] . The use of sedatives during therapeutic endoscopy potentially increases the risk of aspiration pneumonia particularly in the elderly. [@JR1857-17] In the setting of BE-ERCP, the procedure time tends to be longer compared to standard ERCP, potentially increasing the risk of this AE. Attention should be paid not only during endoscopy but also after the post-procedural observation period as the sedative effect may be prolonged due to low drug metabolism in the elderly [@JR1857-36] . Median procedure time in four (1.9 %) elderly patients who developed aspiration pneumonia was as long as 110 minutes.

Furthermore, the multivariable model suggested the association between long procedure time (\> 90 minutes) and increased risk of early AEs ( [Supplementary Table 1](#TB1857-5){ref-type="table"} ). It seems better to avoid lengthy procedures for the elderly to prevent aspiration pneumonia, but a further investigation is required to determine the optimal procedure time for elderly patients receiving BE-ERCP.

Gastrointestinal perforation is another potentially fatal AE associated with BE-ERCP. In the current study, this AE was observed in 15 patients (3 %) including one patient who needed emergent surgery. Considering similar incidences of gastrointestinal perforation reported in the literature [@JR1857-3] [@JR1857-9] [@JR1857-37] , this serious AE is not uncommon in BE-ERCP. Furthermore, advancing age was reported as a risk factor for gastrointestinal perforation after colonoscopy [@JR1857-18] [@JR1857-19] . Perforation in the elderly was supposedly caused by reduction in tissue elasticity or muscle function, not by endoscopic polypectomy or biopsy [@JR1857-19] [@JR1857-35] . Another potential risk factor for gastrointestinal perforation is a type of gastrointestinal reconstruction. Although the Roux-en-Y reconstruction was associated with a procedural failure [@JR1857-38] , Billroth-II reconstruction was a possible risk factor of obvious perforation during BE-ERCP [@JR1857-9] . Contrary to microperforation which could be often managed conservatively, we believe that obvious perforation is the most dreaded AE in BE-ERCP, often necessitating surgical repair. Thus, an indication of BE-ERCP for elderly patients with Billroth-II reconstruction should be considered prudently.

A double balloon endoscope was used in our study, but a single balloon endoscope is another option for ERCP in patients with surgically altered anatomy. Only one retrospective study [@JR1857-39] compared long-type, not short-type, single and double balloon endoscopes for ERCP, and demonstrated similar outcomes between two scopes. Recently, two studies [@JR1857-38] [@JR1857-40] reported clinical outcomes of a short-type single balloon endoscope for ERCP with technical success rates of 81.8 % and 85.9 % and AE rates of 5.9 % and 8.4 %, respectively, which is comparable to our study results. Although there were no studies comparing two short-type balloon endoscopes, it is reasonable to say the type of balloon endoscopes can be selected depending on the local expertise.

The large sample size is a major strength of our study. We performed 1,363 BE-ERCP procedures during the study period and included 568 patients for the analysis. Our study had the largest sample size among previous clinical studies and could give a robust estimation for the safety of BE-ERCP. Furthermore, a prospectively-maintained endoscopy database allowed us to adjust potential confounding variables which could be associated with early AEs.

Our study had limitations. First, the retrospective and single-center design was a limitation; therefore, our findings should be validated in prospective multicenter cohorts. Second, an indication of BE-ERCP in each patient was decided by attending physicians. As we avoided BE-ERCP for patients with poor physical status or highly suspected dysphagia, our study results could not validate the safety of BE-ERCP for these patients. Finally, we consecutively performed BE-ERCP for patients with Billroth-II reconstruction. However, the effectiveness and safety of side- or forward-viewing endoscope was also reported for ERCP in this population [@JR1857-41] . Considering that Billroth-II is the potential risk factor of obvious perforation during BE-ERCP, further comparative study should be conducted in this setting.

Conclusion
==========

In summary, BE-ERCP is a feasible procedure for elderly individuals with surgically altered anatomy. However, indication of BE-ERCP for elderly patients with Billroth-II reconstruction should be selected with a caution because of the potential risk of gastrointestinal perforation. A further validation study is warranted before BE-ERCP can become the gold standard procedure for management of pancreatobiliary diseases among elderly patients with a history of gastrointestinal reconstruction.
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